Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than other prostanoid receptor agonists such as prostaglandin F receptor (FP) agonists.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Invest. Ophthalmol. Vis. Sci.

Title: Investigative ophthalmology & visual science

Publisher: Association for Research in Vision and Ophthalmology (ARVO)

ISSN (Electronic): 1552-5783

ISSN (Print): 0146-0404

Publication date (Electronic): January 01 2018

Volume: 59

Issue: 1

Affiliations

[1 ] R&D Division, Santen Pharmaceutical Co., Ltd., Grand Front Osaka Tower A, Kita-Ku, Osaka, Japan.

[2 ] R&D Division, Santen Pharmaceutical Co., Ltd., Ikoma-shi, Nara, Japan.

[3 ] Corporate Research & Development, Ube Industries, Ltd., Ube, Yamaguchi, Japan.

[4 ] R&D Division, Santen Inc., Emeryville, California, United States.

Article

Publisher Item ID: 2670139

DOI: 10.1167/iovs.17-22745

PubMed ID: 29332128

SO-VID: 9fa03b9b-79fe-406b-8339-fd012e2414ed

History

Data availability:

Comments

Comment on this article

scite_

Cited by 25

See all cited by